Whitehawk Therapeutics, Inc.·4

Apr 3, 6:20 PM ET

BALL BRYAN 4

Research Summary

AI-generated summary

Updated

Whitehawk Therapeutics (WHWK) CTO/SVP Bryan Ball Exercises Options, Receives RSUs

What Happened Bryan Ball — Chief Technical Operations Officer and SVP, Manufacturing Operations — reported transactions on Apr 1, 2026. The Form 4 shows an exercise/conversion of 366,532 derivative securities (code M), a corresponding disposition of 366,532 derivative shares at $0.00, and a grant/acquisition of 250,058 restricted stock units (RSUs) at $0.00. The filing records no cash proceeds for the disposed derivative shares.

Key Details

  • Transaction date: April 1, 2026. Filing date (Accession): April 3, 2026 (timely).
  • Exercise/Conversion (M): 366,532 shares acquired (price listed as N/A).
  • Disposal (M): 366,532 shares disposed @ $0.00 (reported as derivative disposal; $0 proceeds).
  • Grant/Award (A): 250,058 RSUs @ $0.00 (no cash paid).
  • Shares owned after the transactions: not disclosed in this filing.
  • Footnotes:
    • F1: Each RSU represents a contingent right to one share of common stock.
    • F2: The 250,058 RSUs vest 100% on the one-year anniversary of the Vesting Commencement Date (VCD = April 1, 2025) — i.e., subject to continued service, they vest on April 1, 2026.
    • F3: Option vesting schedule referenced (VCD = April 1, 2026): 25% after one year, then monthly vesting over four years (applies to option awards noted).
  • No 10b5-1 plan, tax-withholding sale, or sale proceeds are indicated in the reported entries.

Context RSUs are a grant that convert to shares if vesting conditions are met; here the RSUs are subject to a one-year cliff (vesting date Apr 1, 2026) per the filing. The report shows derivative exercise/conversion activity and a grant rather than an open-market buy or a standard cash sale; because the filing reports $0.00 for disposed derivative shares and N/A for the exercise price, the document does not show any cash proceeds to the insider. This filing is informational about equity-based compensation and conversions rather than a clear cash purchase or sale on the open market.